![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
AC Howlett and RM Fleming
Adenylate cyclase in plasma membranes was inhibited by micromolar concentrations of delta 8-tetrahydrocannabinol and delta 9- tetrahydrocannabinol and by levonantradol and desacetyllevonantradol. This inhibition was noncompetitive for stimulation of the enzyme at the prostanoid receptor by prostaglandin E1 or prostacyclin, or at the peptide receptor by secretin or vasoactive intestinal peptide. Forskolin-activated adenylate cyclase was also inhibited by cannabimimetic agents. Inhibition by cannabinoid compounds was neither synergistic nor additive with muscarinic or alpha-adrenergic agents when each was present at maximally inhibitory concentrations. Cannabinoid inhibition was not blocked by atropine, yohimbine, or naloxone, suggesting that muscarinic, alpha 2-adrenergic and certain opiate receptors may not be required for the response. The inhibition of adenylate cyclase was specific for psychoactive cannabinoids, since cannabinol and cannabidiol produced minimal or no response. Inhibition was also stereoselective, since dextronantradol did not produce the response. A biphasic log dose-response curve was observed for each of the cannabinoid drugs, such that reversal of the inhibition occurred at 3-10 microM. Possible mechanisms for the effects of cannabinoid drugs on adenylate cyclase activity are discussed.
This article has been cited by other articles:
|
|
 |
|
  A. F. Hoffman, M. Oz, R. Yang, A. H. Lichtman, and C. R. Lupica Opposing actions of chronic {Delta}9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation Learn. Mem., January 1, 2007; 14(1-2): 63 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Prestifilippo, J. Fernandez-Solari, C. de la Cal, M. Iribarne, A. M. Suburo, V. Rettori, S. M. McCann, and J. C. Elverdin Inhibition of Salivary Secretion by Activation of Cannabinoid Receptors Experimental Biology and Medicine, September 1, 2006; 231(8): 1421 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Cabral and F. Marciano-Cabral Cannabinoid receptors in microglia of the central nervous system: immune functional relevance J. Leukoc. Biol., December 1, 2005; 78(6): 1192 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bayatti, H. Hermann, B. Lutz, and C. Behl Corticotropin-Releasing Hormone-Mediated Induction of Intracellular Signaling Pathways and Brain-Derived Neurotrophic Factor Expression Is Inhibited by the Activation of the Endocannabinoid System Endocrinology, March 1, 2005; 146(3): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nithipatikom, M. P. Endsley, M. A. Isbell, J. R. Falck, Y. Iwamoto, C. J. Hillard, and W. B. Campbell 2-Arachidonoylglycerol: A Novel Inhibitor of Androgen-Independent Prostate Cancer Cell Invasion Cancer Res., December 15, 2004; 64(24): 8826 - 8830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rinaldi-Carmona, F. Barth, C. Congy, S. Martinez, D. Oustric, A. Perio, M. Poncelet, J. Maruani, M. Arnone, O. Finance, et al. SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 905 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fernandez-Solari, C. Scorticati, C. Mohn, A. De Laurentiis, S. Billi, A. Franchi, S. M. McCann, and V. Rettori Alcohol inhibits luteinizing hormone-releasing hormone release by activating the endocannabinoid system PNAS, March 2, 2004; 101(9): 3264 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Khasabova, C. Harding-Rose, D. A. Simone, and V. S. Seybold Differential Effects of CB1 and Opioid Agonists on Two Populations of Adult Rat Dorsal Root Ganglion Neurons J. Neurosci., February 18, 2004; 24(7): 1744 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hilairet, M. Bouaboula, D. Carriere, G. Le Fur, and P. Casellas Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor: EVIDENCE FOR CROSS-TALK BLOCKED BY THE SPECIFIC CB1 ANTAGONIST, SR141716 J. Biol. Chem., June 20, 2003; 278(26): 23731 - 23737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Straiker and J. M. Sullivan Cannabinoid Receptor Activation Differentially Modulates Ion Channels in Photoreceptors of the Tiger Salamander J Neurophysiol, May 1, 2003; 89(5): 2647 - 2654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Lee, F. L. Smith, D. L. Stevens, and S. P. Welch The Role of Several Kinases in Mice Tolerant to Delta 9-Tetrahydrocannabinol J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 593 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Scorticati, C. Mohn, A. De Laurentiis, P. Vissio, J. Fernandez Solari, A. Seilicovich, S. M. McCann, and V. Rettori The effect of anandamide on prolactin secretion is modulated by estrogen PNAS, February 18, 2003; 100(4): 2134 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Martin Identification of the Endogenous Cannabinoid System through Integrative Pharmacological Approaches J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 790 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ohno-Shosaku, H. Tsubokawa, I. Mizushima, N. Yoneda, A. Zimmer, and M. Kano Presynaptic Cannabinoid Sensitivity Is a Major Determinant of Depolarization-Induced Retrograde Suppression at Hippocampal Synapses J. Neurosci., May 15, 2002; 22(10): 3864 - 3872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nie and D. L. Lewis Structural Domains of the CB1 Cannabinoid Receptor That Contribute to Constitutive Activity and G-Protein Sequestration J. Neurosci., November 15, 2001; 21(22): 8758 - 8764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Morisset and L. Urban Cannabinoid-Induced Presynaptic Inhibition of Glutamatergic EPSCs in Substantia Gelatinosa Neurons of the Rat Spinal Cord J Neurophysiol, July 1, 2001; 86(1): 40 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Valverde, R. Maldonado, E. Valjent, A. M. Zimmer, and A. Zimmer Cannabinoid Withdrawal Syndrome Is Reduced in Pre-Proenkephalin Knock-Out Mice J. Neurosci., December 15, 2000; 20(24): 9284 - 9289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Klein, C. A. Newton, N. Nakachi, and H. Friedman {Delta}9-Tetrahydrocannabinol Treatment Suppresses Immunity and Early IFN-{gamma}, IL-12, and IL-12 Receptor {beta}2 Responses to Legionella pneumophila Infection J. Immunol., June 15, 2000; 164(12): 6461 - 6466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Takahashi and D. J. Linden Cannabinoid Receptor Modulation of Synapses Received by Cerebellar Purkinje Cells J Neurophysiol, March 1, 2000; 83(3): 1167 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Martin, R. Jefferson, R. Winckler, J. L. Wiley, J. W. Huffman, P. J. Crocker, B. Saha, and R. K. Razdan Manipulation of the Tetrahydrocannabinol Side Chain Delineates Agonists, Partial Agonists, and Antagonists J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1065 - 1079. [Abstract] [Full Text]
|
|
|
|
 |
|
 Q. Tao, S. D. McAllister, J. Andreassi, K. W. Nowell, G. A. Cabral, D. P. Hurst, K. Bachtel, M. C. Ekman, P. H. Reggio, and M. E. Abood Role of a Conserved Lysine Residue in the Peripheral Cannabinoid Receptor (CB2): Evidence for Subtype Specificity Mol. Pharmacol., March 1, 1999; 55(3): 605 - 613. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. Bonhaus, L. K. Chang, J. Kwan, and G. R. Martin Dual Activation and Inhibition of Adenylyl Cyclase by Cannabinoid Receptor Agonists: Evidence for Agonist-Specific Trafficking of Intracellular Responses J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 884 - 888. [Abstract] [Full Text]
|
|
|
|
|
|
M. Rinaldi-Carmona, A. Le Duigou, D. Oustric, F. Barth, M. Bouaboula, P. Carayon, P. Casellas, and G. Le Fur Modulation of CB1 Cannabinoid Receptor Functions after a Long-Term Exposure to Agonist or Inverse Agonist in the Chinese Hamster Ovary Cell Expression System J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1038 - 1047. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Carayon, J. Marchand, D. Dussossoy, J.-M. Derocq, O. Jbilo, A. Bord, M. Bouaboula, S. Galiegue, P. Mondiere, G. Penarier, et al. Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation Blood, November 15, 1998; 92(10): 3605 - 3615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C.-K. Chan, T. R. Hinds, S. Impey, and D. R. Storm Hippocampal Neurotoxicity of Delta 9-Tetrahydrocannabinol J. Neurosci., July 15, 1998; 18(14): 5322 - 5332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Griffin, P. J. Atkinson, V. M. Showalter, B. R. Martin, and M. E. Abood Evaluation of Cannabinoid Receptor Agonists and Antagonists Using the Guanosine-5'-O-(3-[35S]thio)-triphosphate Binding Assay in Rat Cerebellar Membranes J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 553 - 560. [Abstract] [Full Text]
|
|
|
|
|
|
Q. Tao and M. E. Abood Mutation of a Highly Conserved Aspartate Residue in the Second Transmembrane Domain of the Cannabinoid Receptors, CB1 and CB2, Disrupts G-Protein Coupling J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 651 - 658. [Abstract] [Full Text]
|
|
|
|
|
|
M. Rinaldi-Carmona, F. Barth, J. Millan, J.-M. Derocq, P. Casellas, C. Congy, D. Oustric, M. Sarran, M. Bouaboula, B. Calandra, et al. SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 644 - 650. [Abstract] [Full Text]
|
|
|
|
|
|
C. S. Breivogel, L. J. Sim, and S. R. Childers Regional Differences in Cannabinoid Receptor/G-protein Coupling in Rat Brain J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1632 - 1642. [Abstract] [Full Text]
|
|
|
|
|
|
M. Bouaboula, S. Perrachon, L. Milligan, X. Canat, M. Rinaldi-Carmona, M. Portier, F. Barth, B. Calandra, F. Pecceu, J. Lupker, et al. A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1. EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS J. Biol. Chem., August 29, 1997; 272(35): 22330 - 22339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bayewitch, M.-H. Rhee, T. Avidor-Reiss, A. Breuer, R. Mechoulam, and Z. Vogel (-)-Delta^9-Tetrahydrocannabinol Antagonizes the Peripheral Cannabinoid Receptor-mediated Inhibition of Adenylyl Cyclase J. Biol. Chem., April 26, 1996; 271(17): 9902 - 9905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bouaboula, B. Bourrié, M. Rinaldi-Carmona, D. Shire, Gér. L. Fur, and P. Casellas Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells J. Biol. Chem., June 9, 1995; 270(23): 13973 - 13980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Shire, C. Carillon, M. Kaghad, B. Calandra, M. Rinaldi-Carmona, Gér. Le Fur, D. Caput, and P. Ferrara An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing J. Biol. Chem., February 24, 1995; 270(8): 3726 - 3731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kim and S. A. Thayer Cannabinoids Inhibit the Formation of New Synapses between Hippocampal Neurons in Culture J. Neurosci., May 15, 2001; 21(10): RC146 - RC146. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
